BRPI0706511A2 - marcadores de expressão genética para prognóstico de cáncer colorretal - Google Patents

marcadores de expressão genética para prognóstico de cáncer colorretal Download PDF

Info

Publication number
BRPI0706511A2
BRPI0706511A2 BRPI0706511-6A BRPI0706511A BRPI0706511A2 BR PI0706511 A2 BRPI0706511 A2 BR PI0706511A2 BR PI0706511 A BRPI0706511 A BR PI0706511A BR PI0706511 A2 BRPI0706511 A2 BR PI0706511A2
Authority
BR
Brazil
Prior art keywords
expression
evidence
cancer
genes
listed
Prior art date
Application number
BRPI0706511-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Cowens Wayne
B. Baker Joffre
Clark Kim
Hackett James
Watson Drew
Paik Soonmyung
Original Assignee
Genomic Health, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health, Inc. filed Critical Genomic Health, Inc.
Publication of BRPI0706511A2 publication Critical patent/BRPI0706511A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0706511-6A 2006-01-11 2007-01-11 marcadores de expressão genética para prognóstico de cáncer colorretal BRPI0706511A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75839206P 2006-01-11 2006-01-11
US60/758,392 2006-01-11
US80027706P 2006-05-12 2006-05-12
US60/800,277 2006-05-12
US81007706P 2006-05-31 2006-05-31
US60/810,077 2006-05-31
PCT/US2007/000995 WO2007082099A2 (en) 2006-01-11 2007-01-11 Gene expression markers for colorectal cancer prognosis

Publications (1)

Publication Number Publication Date
BRPI0706511A2 true BRPI0706511A2 (pt) 2011-03-29

Family

ID=38257063

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0706511-6A BRPI0706511A2 (pt) 2006-01-11 2007-01-11 marcadores de expressão genética para prognóstico de cáncer colorretal

Country Status (14)

Country Link
US (10) US7695913B2 (https=)
EP (9) EP1974058B1 (https=)
JP (7) JP5297202B2 (https=)
KR (1) KR20090003178A (https=)
AU (1) AU2007204826B2 (https=)
BR (1) BRPI0706511A2 (https=)
CA (1) CA2636984A1 (https=)
DK (1) DK1974058T3 (https=)
ES (1) ES2491222T3 (https=)
IL (1) IL192794A (https=)
MX (1) MX2008008973A (https=)
NO (1) NO20083461L (https=)
NZ (7) NZ593226A (https=)
WO (1) WO2007082099A2 (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046386A1 (en) 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
ES2636470T3 (es) 2004-04-09 2017-10-05 Genomic Health, Inc. Marcadores de expresión génica para predecir la respuesta a la quimioterapia
NZ593226A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US20090076734A1 (en) 2007-03-22 2009-03-19 Torres-Roca Javier F Gene Signature for the Prediction of Radiation Therapy Response
US20080234946A1 (en) * 2007-03-22 2008-09-25 University Of South Florida Predictive radiosensitivity network model
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
US20090123920A1 (en) * 2007-11-08 2009-05-14 Maher Albitar Jak2 mutations
ES2332167B1 (es) * 2007-12-04 2010-10-25 Universidad Autonoma De Madrid Empleo de trefoil factor-family 3 (tff3) en el pronostico de sujetos diagnosticados con cancer colorectal.
WO2009123634A1 (en) * 2008-04-02 2009-10-08 Regents Of The University Of California Systems and methods for predicting response of biological samples
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
NZ589143A (en) 2008-05-14 2012-02-24 Genomic Health Inc Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels
US20100029748A1 (en) * 2008-08-04 2010-02-04 Sloan-Kettering Institute For Cancer Research Metastasis Promoting Genes and Proteins
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
US20110257034A1 (en) * 2008-10-10 2011-10-20 Cornell University Methods for identifying genes which predict disease outcome for patients with colon cancer
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US8765383B2 (en) * 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
WO2010127322A1 (en) * 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
TWI513465B (zh) * 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
SG186953A1 (en) 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
IL243203A (en) 2010-07-27 2017-04-30 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
CN103415624B (zh) 2010-08-13 2017-03-01 私募蛋白质体公司 胰腺癌生物标记及其用途
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
EP2619574B1 (en) 2010-09-15 2020-10-28 Almac Diagnostic Services Limited Molecular test for predicting responsiveness to dna-damage therapeutic agents in individuals having cancer
KR20140006898A (ko) * 2011-01-25 2014-01-16 알막 다이아그노스틱스 리미티드 결장암 유전자 발현 시그니처 및 이용 방법
US10308980B2 (en) 2011-11-04 2019-06-04 Oslo Universitetssykehus Hf Methods and biomarkers for analysis of colorectal cancer
CN104053788A (zh) 2011-11-28 2014-09-17 加泰罗尼亚调查和高级研究机构 结肠直肠癌的预后方法和试剂盒
EP2794924B1 (en) 2011-12-22 2019-02-06 Baylor Research Institute Identification of mirna signatures in human colorectal cancer
US9822417B2 (en) 2012-01-09 2017-11-21 Oslo Universitetssykehus Hf Methods and biomarkers for analysis of colorectal cancer
DK3179393T3 (da) 2012-01-31 2020-07-27 Genomic Health Inc Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft
WO2013150167A2 (es) 2012-04-03 2013-10-10 Servicio Andaluz De Salud Modelo de expresión de microarn como indicador de supervivencia en pacientes de cancer colorrectal metastásico
WO2014077915A1 (en) * 2012-11-14 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
CA2891653A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
ES2475366B1 (es) * 2012-12-10 2015-05-05 Fundación Imdea Alimentación Métodos y kits para el pronóstico del cáncer colorrectal
US20140272969A1 (en) 2013-03-14 2014-09-18 Abbott Molecular Inc. Cell preparations and cell supports and their use in theranosis
CA2902916C (en) 2013-03-14 2018-08-28 Mayo Foundation For Medical Education And Research Detecting neoplasm
WO2014191559A1 (en) * 2013-05-30 2014-12-04 Institució Catalana De Recerca I Estudis Avançats Methods and kits for the prognosis of colorectal cancer
US10185809B1 (en) * 2013-10-15 2019-01-22 Iqvia Inc. Patient projection methodology
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
MX2016012697A (es) * 2014-03-28 2017-05-09 Applied Proteomics Inc Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
CA2947624A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US20170275700A1 (en) 2014-08-14 2017-09-28 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
CA2965217A1 (en) 2014-10-24 2016-04-28 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
BR112017007962A2 (pt) 2014-10-24 2018-01-23 Koninklijke Philips Nv método implementado por computador, aparelho, mídia de armazenamento, programa de computador, kit, e, uso do kit
ES2833543T3 (es) 2014-10-24 2021-06-15 Koninklijke Philips Nv Evaluación de la actividad de la ruta de señalización celular de TGF usando modelos matemáticos de la expresión de genes diana
JP6072396B2 (ja) 2014-11-25 2017-02-01 三菱電機株式会社 空圧式アクチュエータ
US20180148789A1 (en) * 2014-12-01 2018-05-31 University Of Southern California Methods for treating and assessing tumor invasion and metastasis
EP3073268A1 (en) * 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
US10435755B2 (en) 2015-03-27 2019-10-08 Exact Sciences Development Company, Llc Detecting esophageal disorders
WO2016164815A1 (en) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
WO2016208776A1 (ja) * 2015-06-25 2016-12-29 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
CA2995520A1 (en) 2015-08-14 2017-02-23 Hendrik Jan VAN OOIJEN Assessment of nfkb cellular signaling pathway activity using mathematical modelling of target gene expression
CN114574585A (zh) 2015-08-31 2022-06-03 梅约医药教育及研究基金会 检测胃肿瘤
EP3466446B1 (en) 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
JP6432962B2 (ja) 2016-03-29 2018-12-05 株式会社国際電気通信基礎技術研究所 腎機能低下、慢性腎疾患及び腎不全からなる群から選択される少なくとも一種の疾患を予防、又は治療するための有効成分の候補物質のスクリーニング方法
AU2017261688B2 (en) 2016-05-10 2022-09-29 Mayo Foundation For Medical Education And Research Methods and materials for staging and treating skin cancer
US11746381B2 (en) 2017-03-10 2023-09-05 Cancer Diagnostics Research Innvovations, LLC Methods for diagnosing and treating gastric cancer using miRNA expression
WO2018224731A1 (en) * 2017-06-05 2018-12-13 Ls Cancerdiag Oy A method for determining whether a subject is at risk to develop cancer and tools related thereto
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3461916A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
JP7027179B2 (ja) * 2018-01-24 2022-03-01 キヤノン株式会社 給送回転体、シート給送装置及び画像形成装置
AU2019230200A1 (en) * 2018-03-08 2020-10-29 University Of Notre Dame Du Lac Systems and methods for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon
KR102007450B1 (ko) * 2018-05-31 2019-08-05 한국과학기술연구원 대장암 치료제 발굴을 위한 신규 표적 치료 작용점의 스크리닝 방법 및 이를 이용하여 선별한 대장암 치료 예후 바이오마커
CN113039289B (zh) 2018-07-25 2025-11-07 斯凯莱恩迪艾克斯有限公司 预测黑色素瘤转移和患者预后的基因特征
WO2020112853A1 (en) 2018-11-28 2020-06-04 Genascence Corporation Methods and compositions for treating osteoarthritis
WO2020123699A1 (en) * 2018-12-11 2020-06-18 The Trustees Of Columbia University In The City Of New York Compounds and compositions that cause mycn and/or cmyc degradation and methods of use thereof
CN110257518B (zh) * 2019-07-01 2022-08-02 复旦大学附属中山医院 一种用于预测转移性结直肠癌转化治疗疗效的基因集
US12057959B2 (en) * 2019-12-31 2024-08-06 Mcafee, Llc Device identification
KR102263984B1 (ko) * 2020-02-21 2021-06-11 재단법인 아산사회복지재단 직장암 환자에서 수술-전 화학방사선치료의 반응을 예측하기 위한 분석방법
KR102535150B1 (ko) * 2020-04-14 2023-05-23 주식회사 베르티스 암의 예후 예측용 조성물
JP2023524016A (ja) * 2020-04-29 2023-06-08 フリーノム ホールディングス，インク． 結腸細胞増殖性障害を特定するためのｒｎａマーカと方法
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN112322730B (zh) * 2020-10-16 2023-04-18 上海市第一人民医院 预测肿瘤耐药、复发的标志物kifc1及其抑制剂和应用
EP4026918A1 (en) * 2021-01-12 2022-07-13 Koninklijke Philips N.V. Prediction of an outcome of a colorectal cancer subject
CN113667673B (zh) * 2021-07-15 2024-02-06 武汉血液中心 一种类孟买血型FUT1 236delG等位基因及其检测方法和应用
KR20230059642A (ko) * 2021-10-26 2023-05-03 사회복지법인 삼성생명공익재단 miRNA를 포함하는 대장암의 치료 및 전이 억제용 조성물 및 이의 용도
CN116735874B (zh) * 2022-03-11 2025-09-23 上海市免疫学研究所 结直肠癌肿瘤边界细胞亚群标志物组合及其应用
US20260043086A1 (en) * 2022-08-06 2026-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Predictive biomarker in avastin in colon cancer

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020172987A1 (en) 1998-02-12 2002-11-21 Terstappen Leon W.M.M. Methods and reagents for the rapid and efficient isolation of circulating cancer cells
WO1999064627A2 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
WO1999064626A2 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
WO2000024940A1 (en) 1998-10-28 2000-05-04 Vysis, Inc. Cellular arrays and methods of detecting and using genetic disorder markers
EP0999016B1 (en) * 1998-11-06 2001-07-11 Temco S. R. L. Cutter for cross cutting of webs
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
CA2384713A1 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
US20010044414A1 (en) 1999-12-10 2001-11-22 Whitehead Institute For Biomedical Research Metastasis genes and uses thereof
US7029677B2 (en) * 2000-01-25 2006-04-18 Nuvelo, Inc. Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
WO2001077375A2 (en) 2000-04-06 2001-10-18 Epigenomics Ag Diagnosis of diseases associated with gene regulation
WO2005000087A2 (en) 2003-06-03 2005-01-06 Chiron Corporation Gene products differentially expressed in cancerous colon cells and their methods of use ii
AU2001290518A1 (en) 2000-08-03 2002-02-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030166064A1 (en) 2000-08-03 2003-09-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
CA2417866A1 (en) 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20030077568A1 (en) 2000-09-15 2003-04-24 Gish Kurt C. Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
EP1339872A2 (en) 2000-09-19 2003-09-03 Whitehead Institute For Biomedical Research Genetic markers for tumors
WO2002058534A2 (en) 2000-11-20 2002-08-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
AU2002251844A1 (en) * 2001-02-02 2002-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20020197633A1 (en) * 2001-05-09 2002-12-26 Jones Brian C. Evaluation of ultraviolet radiation damage to skin using new gene markers, methods and compositions related thereto
US20030148314A1 (en) 2001-08-01 2003-08-07 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US6964850B2 (en) 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20030225526A1 (en) 2001-11-14 2003-12-04 Golub Todd R. Molecular cancer diagnosis using tumor gene expression signature
AU2002357747A1 (en) * 2001-12-10 2003-06-23 Millennium Pharmaceuticals Inc. Novel genes encoding colon cancer antigens
AU2003209340A1 (en) 2002-01-18 2003-09-02 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
US7955800B2 (en) 2002-06-25 2011-06-07 Advpharma Inc. Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients
WO2004025258A2 (en) 2002-09-10 2004-03-25 Sydney Kimmel Cancer Center Gene segregation and biological sample classification methods
EP1560597A4 (en) 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED CANCER GENES, POLYPEPTIDES CODED THEREIN, AND METHOD OF USE THEREOF
WO2004074518A1 (en) 2003-02-20 2004-09-02 Genomic Health, Inc. Use of intronic rna to measure gene expression
AU2004258085B2 (en) 2003-07-10 2010-05-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20050014165A1 (en) 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
WO2005015236A2 (en) 2003-07-18 2005-02-17 Roche Diagnostics Gmbh A method for predicting the progression of adenocarcinoma
WO2005012875A2 (en) * 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
EP1522594A3 (en) 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
WO2005100593A1 (en) 2004-04-16 2005-10-27 Monash University A method for monitoring the progress of cancer
US20080032293A1 (en) 2004-07-15 2008-02-07 The University Of North Carolina At Chapel Hill Housekeeping Genes And Methods For Identifying Same
US20060183893A1 (en) 2005-01-25 2006-08-17 North Don A Nucleic acids for apoptosis of cancer cells
CA2604844A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
AU2006259583A1 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
WO2007070621A2 (en) 2005-12-13 2007-06-21 Children's Medical Center Corporation Prognosis indicators for solid human tumors
NZ544432A (en) 2005-12-23 2009-07-31 Pacific Edge Biotechnology Ltd Prognosis prediction for colorectal cancer using a prognositc signature comprising markers ME2 and FAS
NZ593226A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
US20100009905A1 (en) 2006-03-24 2010-01-14 Macina Roberto A Compositions and Methods for Detection, Prognosis and Treatment of Colon Cancer
CA2680591A1 (en) 2007-03-15 2008-09-25 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
WO2010127322A1 (en) 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy

Also Published As

Publication number Publication date
US20120171688A1 (en) 2012-07-05
NZ593225A (en) 2012-10-26
ES2491222T3 (es) 2014-09-05
US8273537B2 (en) 2012-09-25
WO2007082099A2 (en) 2007-07-19
JP2013223503A (ja) 2013-10-31
JP5486720B2 (ja) 2014-05-07
JP2013176398A (ja) 2013-09-09
KR20090003178A (ko) 2009-01-09
NZ593224A (en) 2012-10-26
NZ593226A (en) 2012-10-26
US20090291434A1 (en) 2009-11-26
US8153380B2 (en) 2012-04-10
JP2013226151A (ja) 2013-11-07
US8153378B2 (en) 2012-04-10
EP2377950A1 (en) 2011-10-19
US8198024B2 (en) 2012-06-12
EP2412822A1 (en) 2012-02-01
JP5486719B2 (ja) 2014-05-07
JP2013226150A (ja) 2013-11-07
AU2007204826B2 (en) 2013-01-10
JP5297202B2 (ja) 2013-09-25
EP2412824B1 (en) 2014-10-08
US20110039270A1 (en) 2011-02-17
JP5486664B2 (ja) 2014-05-07
JP2013215201A (ja) 2013-10-24
EP2412823B1 (en) 2014-09-03
EP2412821A1 (en) 2012-02-01
JP5486717B2 (ja) 2014-05-07
NZ593229A (en) 2012-10-26
JP2009523028A (ja) 2009-06-18
US20110111421A1 (en) 2011-05-12
AU2007204826A1 (en) 2007-07-19
WO2007082099A3 (en) 2008-01-17
NZ593228A (en) 2012-10-26
NZ569788A (en) 2011-08-26
US8153379B2 (en) 2012-04-10
EP2412821B1 (en) 2014-09-17
US8367345B2 (en) 2013-02-05
US7695913B2 (en) 2010-04-13
EP2412824A1 (en) 2012-02-01
EP1974058B1 (en) 2014-06-11
US20110097759A1 (en) 2011-04-28
CA2636984A1 (en) 2007-07-19
EP2407553A1 (en) 2012-01-18
NO20083461L (no) 2008-10-10
NZ593227A (en) 2012-10-26
EP2377950B1 (en) 2014-09-17
JP2013074894A (ja) 2013-04-25
US8029995B2 (en) 2011-10-04
EP2412820A1 (en) 2012-02-01
MX2008008973A (es) 2008-11-26
US20110039272A1 (en) 2011-02-17
US20110039269A1 (en) 2011-02-17
US8026060B2 (en) 2011-09-27
HK1120089A1 (en) 2009-03-20
EP2400036A1 (en) 2011-12-28
DK1974058T3 (da) 2014-09-01
IL192794A (en) 2013-07-31
EP2412823A1 (en) 2012-02-01
JP5486718B2 (ja) 2014-05-07
IL192794A0 (en) 2009-02-11
US20110039271A1 (en) 2011-02-17
US20100190173A1 (en) 2010-07-29
EP1974058A2 (en) 2008-10-01
US20130102492A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
JP5486664B2 (ja) 結腸直腸癌の予後のための遺伝子発現マーカー
JP6351112B2 (ja) 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験
JP6190434B2 (ja) 化学療法剤に対する応答を予測するための遺伝子発現マーカー
JP4680898B2 (ja) 癌再発の可能性の予測
JP6246845B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
US8632980B2 (en) Gene expression markers for prediction of patient response to chemotherapy
US20110123990A1 (en) Methods To Predict Clinical Outcome Of Cancer
WO2008115419A2 (en) Gene expression markers for prediction of patient response to chemotherapy
JP2007507222A (ja) 化学療法に対する応答を予測するための遺伝子発現マーカー
CN101400804B (zh) 用于结肠直肠癌预后的基因表达标志物
US20110287958A1 (en) Method for Using Gene Expression to Determine Colorectal Tumor Stage
HK40014990A (en) Methods to predict clinical outcome of cancer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2342 DE 24-11-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.